BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 15065220)

  • 1. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
    Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
    Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes: enhancement of opioid efficacy in inhibiting adenylyl cyclase.
    Côté TE; Izenwasser S; Weems HB
    J Pharmacol Exp Ther; 1993 Oct; 267(1):238-44. PubMed ID: 8229750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional coupling of a mu opioid receptor to G proteins and adenylyl cyclase: modulation by chronic morphine treatment.
    Chen Y; Liu J; Yu L
    Addict Biol; 1996; 1(1):49-59. PubMed ID: 12893486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
    Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB
    Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
    Selley DE; Liu Q; Childers SR
    J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic morphine up-regulates G alpha12 and cytoskeletal proteins in Chinese hamster ovary cells expressing the cloned mu opioid receptor.
    Xu H; Wang X; Zimmerman D; Boja ES; Wang J; Bilsky EJ; Rothman RB
    J Pharmacol Exp Ther; 2005 Oct; 315(1):248-55. PubMed ID: 15987828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular cAMP assay and Eu-GTP-γS binding studies of chimeric opioid peptide YFa.
    Kumar K; Kumar S; Kurupati RK; Seth MK; Mohan A; Hussain ME; Pasha S
    Eur J Pharmacol; 2011 Jan; 650(1):28-33. PubMed ID: 20887721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
    Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
    Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic morphine treatment increases stimulatory beta-2 adrenoceptor signaling in A431 cells stably expressing the mu opioid receptor.
    Ammer H; Schulz R
    J Pharmacol Exp Ther; 1997 Jan; 280(1):512-20. PubMed ID: 8996236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemical analysis of methadone modulation on morphine-induced tolerance and dependence in the rat brain.
    He L; Whistler JL
    Pharmacology; 2007; 79(4):193-202. PubMed ID: 17356311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.